Last reviewed · How we verify
NCT06918626: INACCESSIBLE
INtraoperative Approach With Eventual Clearance of Common bilE Duct by SpyGlass Discover vs Sequential Strategy in Patients With Acute Calculus Cholecystitis and Intermediate/High Risk of Common BiLE Duct Stone
NA trial testing ELC + Spyglass cholangiography in Acute Calculous Cholecystitiis (ACC) in 62 participants. Currently enrolling.
30 May 2025
Quick facts
| Lead sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 62 |
| Start date | 18 February 2024 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- ELC + Spyglass cholangiography
- ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures
Conditions studied
- Acute Calculous Cholecystitiis (ACC) — all drugs for Acute Calculous Cholecystitiis (ACC) →
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Who can join
18 and older, any sex, with Acute Calculous Cholecystitiis (ACC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
INACCESSIBLE trial is a randomized controlled study that compares two different strategies for the treatment of Acute Calculous Cholecystitiis (ACC) patients with high/intermediate risk of CBDS, according to the score by Khoury T (named Israelian Score, IS). If a patient meets the inclusion and exclusion criteria, (s)he will be randomized to receive ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures (control group) or ELC + Spyglass cholangiography (study group). The follow-up will be performed after 30 days and 6 months from intervention with an outpatient medical examination
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06918626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondazione IRCCS Policlinico San Matteo di Pavia trials
Trials by the same sponsor.
- NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
- NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
- NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
- NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
- NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06918626 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06918626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing